A study of pasireotide versus octreotide (C2305) in 358 patients with medically naïve acromegaly found biochemical disease control, defined as GH < 2.5 μg/L and IGF-I within the age-related reference interval at 12 months, significantly more often in patients treated with pasireotide (31.3% vs 19.2%; p = 0.007) (13). Here, GH1 is linked to acromegaly.